NCT00502996View on ClinicalTrials.gov

A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.

PHASE3CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Methotrexate

\>=15 mg po/week

DRUG

rituximab [MabThera/Rituxan]

1g iv on days 1 and 15

Trial Locations (49)

13

Lima

1010

Caracas

1040

Caracas

1394

Cuenca

Quito

1425

Buenos Aires

3005

Barquisimeto

4000

San Miguel de Tucumán

5000

Córdoba

11600

Montevideo

14080

Mexico City

78240

San Luis Potosí City

22640102

Rio de Janeiro

70322000

Brasília

74110010

Goiânia

C1280AEB

Buenos Aires

C1426AAL

Buenos Aires

66063-240

Belém

70390-904

Brasília

13015-001

Campinas

13025-141

Campinas

80730-000

Curitiba

88040-970

Florianópolis

60155-290

Fortaleza

60430-370

Fortaleza

34000-000

Nova Lima

90610-000

Porto Alegre

50000-000

Recife

14048-900

Ribeirão Preto

20551-030

Rio de Janeiro

21941-590

Rio de Janeiro

22050-000

Rio de Janeiro

40050-410

Salvador

03128-050

São Paulo

04026-000

São Paulo

04038-002

São Paulo

04038-040

São Paulo

04039-004

São Paulo

05403-000

São Paulo

29043-910

Vitória

Unknown

Santiago

Barranquilla

Bogotá

Guayaquil

San Salvador

Jesus Maria

02990

Mexico City

06920

Mexico City

LIMA 27

San Isidro

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00502996 - A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis. | Biotech Hunter | Biotech Hunter